Clinical trial · Interventional
Clinical Study of Effectiveness of Radiotherapy Before Surgery in High-risk Relapse Hepatocellular Cancer Patients
Effectiveness of Radiotherapy Before Surgery in Patients With High-risk Relapse Hepatocellular Carcinoma
NCT02580929CI-TRIAL-00019556unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate the effectiveness of radiotherapy before surgery in high-risk relapse hepatocellular cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Hepatocellular | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- radiation
- interventionNames
- Radiation: radiotherapy
- type
- NO_INTERVENTION
- label
- no radiation
Primary outcomes (1)
- measure
- mortality
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Clinical diagnosis of HCC 2. In high risk of recurrence of HCC but still can endure palliative resection 3. KPS scores are \>90 4. With Child-Pugh Class A liver funcion, serum bilirubin\< 1.5\*normal maxism; ALT and AST\< 1.5\*normal maxism; normal creatinine and urea nitrogen; WBC\>4×109/L, Hb\>110g/L, PLT\>90X109/L. 5. Have signed informed consent Exclusion Criteria: 1. HCC cannot be operated 2. With Child-Pugh Class B/C 3. Have other organ cancer, excluding curative non-melanotic skin cancer and carcinoma in situ of cervix 4. Have other severe disease 5. With active hepatitis 6. Have accepted local radiation therapy in other hospitals 7. KPS scores≤70 8. Tumor edges cannot be defined 9. Have severe cirrhosis complication 10. Intensity modulated radiation therapy cannot reach required dose 11. Cannot cooperate 12. Lactant or pregnant 13. Cannnot be informed
References
Publications (1)
- DERIVEDWu F, Chen B, Dong D, Rong W, Wang H, Wang L, Wang S, Jin J, Song Y, Liu Y, Fang H, Tang Y, Li N, Zhu X, Li Y, Wang W, Wu J. Phase 2 Evaluation of Neoadjuvant Intensity-Modulated Radiotherapy in Centrally Located Hepatocellular Carcinoma: A Nonrandomized Controlled Trial. JAMA Surg. 2022 Dec 1;157(12):1089-1096. doi: 10.1001/jamasurg.2022.4702. PMID 36197682